PubMed Health⌕ Search

Biomedical subjects

L Moretti

Publications and source records attributed to L Moretti.

79 records · Page 5Linked to original sources
PubMedDate not supplied

Quantitation of T cell depletion by limiting dilution analysis.

BACKGROUND: We evaluated a culture method for enumeration of residual T cells remaining in marrow after treatment with antibody and complement or with immunotoxin. METHODS: Marrow cells were cultured at limiting dilutions with phytohemagglutinin in the presence of Epstein Barr virus transformed human lymphoblastoid cells, and supernates were tested three days later for IL-2 by a cell proliferation assay. This method provides a simple, reliable, objective and rapid enumeration of T cells in marrow before and after treatment. RESULTS: Approximately 6% of untreated marrow mononuclear cells can produce IL-2 in such clonal cultures. Treatment with antibodies and complement under conditions identical to those used for our previous clinical trials produced a 3.7 log depletion of IL-2 precursors, whereas treatment with a ricin A chain anti-CD3 immunotoxin produced a 3.0 log depletion. CONCLUSIONS: Clinical correlations are in progress for assessing whether T cell depletion evaluated with the present method equals previous techniques. The extreme depletion of T cells accomplished by these methods may partly account for the high graft failure rate seen in our clinical trials.

Antibodies, Monoclonal↗
PubMedDate not supplied

Retinal vasculitis in rheumatoid arthritis: an angiographic study.

The authors studied sixty patients affected by classical or definite rheumatoid arthritis (RA), to evaluate the possible existence of retinal vasculitis, by employing fluorescein angiography. Retinal vasculitis was found in 18% of the examined patients, even if no clinical and ophthalmoscopic signs of retinal vessel inflammation were present. The authors suggest that the retina should be examined in RA patients, since retinal vasculitis may be asymptomatic at the beginning, but can represent one of the possible extra-articular manifestations of the disease.

Adult↗
PubMedDate not supplied

Allogeneic bone marrow transplantation for hematological malignancies following therapy with high doses of busulphan and cyclophosphamide.

Thirty patients with malignant hematological disease underwent allogeneic bone marrow transplantation following Busulphan (Bu) and Cyclophosphamide (Cy). The diseases were chronic myelogenous leukemia, acute lymphoblastic and non lymphoblastic leukemia, myelofibrosis and multiple myeloma in complete remission and in relapse. A sustained disease-free survival (DFS) was achieved in 0/5 acute leukemia patients transplanted in relapse, in 5/7 acute leukemia patients transplanted in remission (600-1550 days) and in 6/9 CML patients transplanted in the chronic phase of the disease (500-950 days). A sustained DFS was also achieved in one 2nd BMT for relapsed CML. The data suggest that the Bu-Cy protocol combines high tumor ablative capability with toxicity comparable to previously described conditioning regimens for allogeneic BMT, particularly in diseases involving a great expansion of the bone marrow.

Adolescent↗
PubMedDate not supplied

[Bone marrow transplant in acute leukemia in children. Experience of the Pesaro group].

Thirty children aged one to 15 years with acute lymphoblastic leukemia and acute nonlymphoblastic leukemia were transplanted from HLA matched donors using two different preparative regimens: 18 patients were prepared with cyclophosphamide and Total Body Irradiation while 12 patients received Busulphan and Cyclophosphamide. 15 patients survive 7 to 74 months after transplant. Although for the second group of patients a longer follow-up is needed in order to evaluate eradication of the disease and long-term toxicity, the combination chemotherapy alone results in improving survival (71% versus 28%) and decreasing relapse rate (30% versus 56%) compared with the group of patients who received the chemoradiotherapy regimen. Also the incidence of Interstitial Pneumonia has been lower in the group receiving chemotherapy alone. We conclude that this protocol is generally well tolerated in young patients, without increasing secondary toxicity.

Adolescent↗